8-K: Cryoport Reports In-Line FY 2024 Revenue, Eyes Profitability in 2025

Cryoport's FY 2024 revenue reached $228.4 million, aligning with company guidance, while the company focuses on achieving positive adjusted EBITDA in 2025.

Summary

• Cryoport announced its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• FY 2024 revenue was $228.4 million, in line with company guidance.
• Commercial Cell & Gene Therapy revenue increased by 20% year-over-year to $26 million in FY 2024.
• The company supported a record 701 global clinical trials as of December 31, 2024.
• Gross margin improved to 45.8% in Q4 2024 from 40.6% in the same period last year.
• The company anticipates a return to positive adjusted EBITDA during 2025.
• Net loss for FY 2024 was $114.8 million, compared to a net loss of $99.6 million for FY 2023.
• Adjusted EBITDA for FY 2024 was negative $15.1 million, compared to negative $8.3 million for FY 2023.
• Cryoport held $261.7 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• The company repurchased $185.0 million in aggregate principal amount of its Convertible Senior Notes due in 2026 for $163.2 million.
• Full year 2025 revenue guidance is projected to be in the range of $240 $250 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenue growth was slightly down, the company is showing improvements in gross margin and is projecting positive adjusted EBITDA in 2025. The focus on the growing cell and gene therapy market is also a positive sign.

Positives

• Commercial Cell & Gene Therapy revenue saw significant growth, increasing 20% year-over-year for FY 2024.
• The company is supporting an increasing number of global clinical trials, indicating strong market presence.
• Gross margin improved in Q4 2024, suggesting improved cost management.
• Cryoport is actively working towards achieving positive adjusted EBITDA in 2025.
• The company has a substantial amount of cash and short-term investments on hand.
• Cryoport successfully repurchased a significant portion of its convertible senior notes, reducing its debt burden.
• The company's Life Sciences Services business continued its expansion, partially attributed to the double-digit year-over-year growth in BioStorage/BioServices revenue for both the fourth quarter and full year periods.

Negatives

• Total revenue for FY 2024 decreased by 2.1% compared to FY 2023.
• Life Sciences Products revenue decreased by 16.2% for FY 2024.
• The company reported a net loss of $114.8 million for FY 2024.
• Adjusted EBITDA remained negative for FY 2024, although the company anticipates improvement in 2025.

Risks

• The company's 2025 guidance is subject to various factors outside of its control, including economic conditions, supply chain constraints, and foreign currency fluctuations.
• The company's business could be affected by other factors discussed in Cryoport's SEC reports, including in the 'Risk Factors' section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

Future Outlook

The company provides full year 2025 revenue guidance in the range of $240 $250 million and anticipates a return to positive adjusted EBITDA during 2025.

Management Comments

• Jerrell Shelton, CEO of Cryoport, commented, 'Cryoport ended 2024 with solid results across the company including total full year revenue of $228.4 million, which was in-line with our expectations.'
• Mr. Shelton stated, 'We remain confident that our actions will lead us to a return to positive adjusted EBITDA during 2025 as we further implement our pathway to profitability.'
• Mr. Shelton concluded, 'We are excited about our prospects for this year, and we believe we have all the necessary tools in place to execute on our growth plans and to reach our long-term objective of sustainable profitability.'

Industry Context

Cryoport operates in the life sciences supply chain solutions market, with a focus on cell and gene therapies. The company's growth in this sector reflects the increasing demand for specialized logistics and storage solutions for these advanced therapies. The company is positioning itself to capitalize on the anticipated growth in the Cell & Gene Therapy market.

Comparison to Industry Standards

• It is difficult to compare Cryoport directly to other companies due to its unique focus on the cell and gene therapy supply chain.
• However, companies like FedEx and UPS also offer specialized logistics solutions for the healthcare industry, but they do not have the same level of focus on temperature-controlled solutions for cell and gene therapies.
• Other companies in the biostorage space, such as BioLife Solutions, offer complementary products and services.
• Cryoport's support of 701 global clinical trials indicates a strong market position compared to competitors in the cell and gene therapy logistics space.

Stakeholder Impact

• Shareholders can expect potential growth in the cell and gene therapy market, but should also be aware of the risks associated with economic conditions and supply chain constraints.
• Employees may see opportunities for growth and development as the company expands its services and product offerings.
• Customers can expect continued innovation and improved supply chain solutions for their life sciences products.
• Suppliers may see increased demand for their products and services as Cryoport expands its operations.

Next Steps

• The company intends to grow its leading market position and open additional revenue streams through new services and product introductions.
• Cryoport will supplement growth through potential strategic collaborations and partnerships.
• The company expects to file its Annual Report on Form 10-K with the SEC on March 7, 2025.

Key Dates